<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">RhACE- recombinant human angiotensin-converting enzyme 2 is currently undergoing a Phase-2 clinical trial (NCT04335136) in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). This synthetic version of the ACE2 is being studied on 200 participants in Austria to determine if it can prevent viral entry and reduce viral replication in COVID-19 patients. Results from the study are expected in November 2020.</p>
